What retatrutide is
Retatrutide, also known by its development code LY3437943, does not have an approved FDA label. No indication, mechanism statement, or brand name is available from regulatory labeling at this time, so no approved-use information can be provided.
Trial footprint
Retatrutide has 34 registered clinical trials. Among the trials on record, one Phase 1 study examined LY3437943 in participants with impaired and normal liver function and has been completed. A separate completed Phase 1 study measured calorie consumption and usage in participants with obesity using LY3437943. A currently recruiting study with no assigned phase is looking at body composition and exercise strategies to prevent muscle loss during treatment with a GLP-1 agonist.
FAQ
No. Retatrutide, also known as LY3437943, does not currently have an FDA-approved label or indication. It remains in the research and clinical trial stage.
There are 34 registered clinical trials involving retatrutide. These range from early pharmacology studies, such as liver function research, to studies on body composition and calorie consumption.
Completed Phase 1 studies have looked at how the compound behaves in people with impaired versus normal liver function, and at calorie consumption and usage in participants with obesity. A recruiting study is also examining body composition and exercise alongside GLP-1 agonist treatment.
No FAERS adverse event report data is currently available for retatrutide, so no side effect pattern can be summarized from that source.
LY3437943 is the development code used for retatrutide in clinical trial records before any approved brand name exists.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov DailyMed label check
Updated 2026-08-10